financetom
Business
financetom
/
Business
/
Roper Strikes $1.65 Billion Deal to Buy Autism Therapy Software Provider CentralReach
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Roper Strikes $1.65 Billion Deal to Buy Autism Therapy Software Provider CentralReach
Mar 24, 2025 9:11 AM

11:48 AM EDT, 03/24/2025 (MT Newswires) -- Roper Technologies ( ROP ) said Monday that it agreed to acquire CentralReach, an autism therapy software provider, in a $1.65 billion deal that it expects to close within the next two months.

Roper is buying CentralReach from software investor firm Insight Partners, subject to regulatory approval. The $1.65 billion price tag includes a $200 million tax benefit.

"CentralReach is a fantastic business with clear niche market leadership, mission critical and high (return on investment) solutions, a high recurring revenue mix, and outstanding customer retention, which leads to strong organic revenue growth and excellent cash conversion," Roper Chief Executive Neil Hunn said.

Software and technology company Roper expects about $175 million in revenue contribution and $75 million in earnings before interest, taxes, depreciation, and amortization from CetralReach over a 12-month period ending June 30, 2026. It said CentralReach is anticipated to deliver "sustainable" organic revenue and EBITDA growth of more than 20%.

At the end of January, Roper forecast annual revenue growth of more than 10% for 2025.

In a separate statement, CentralReach said it will continue to operate independently under its current leadership. Its software and services help organizations that serve individuals with autism and intellectual and developmental disabilities.

"With Roper's long-term investment and commitment, CentralReach now has a permanent home where we can continue to scale, innovate, expand our impact, and continue to advance our mission in an even faster and more significant way than we have to date," CentralReach CEO Chris Sullens said.

Insight Partners made a significant investment in CentralReach in 2018. "We are excited to see the company continue its growth and expanding its impact, now with the added strength of Roper," Insight Partners Managing Director Richard Wells said.

Price: 576.39, Change: +4.21, Percent Change: +0.74

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BRIEF-Leizig Thermal Management Co Ltd Files For U.S. IPO
BRIEF-Leizig Thermal Management Co Ltd Files For U.S. IPO
Sep 28, 2024
Sept 27 (Reuters) - LEIZIG THERMAL MANAGEMENT CO LTD: * LEIZIG THERMAL MANAGEMENT CO LTD FILES FOR U.S. IPO - SEC FILING * LEIZIG THERMAL MANAGEMENT CO SEES IPO PRICING BETWEEN $4.00 AND $6.00 PER ORDINARY SHARE- FILING * LEIZIG THERMAL MANAGEMENT CO SAYS INTENDS TO APPLY TO LIST ORDINARY SHARES ON NASDAQ * LEIZIG THERMAL MANAGEMENT CO SAYS REVERE...
Market Chatter: Biden Plan to Ban Chinese Tech in US Cars May Cut Sales by Almost 26,000, Agency Says
Market Chatter: Biden Plan to Ban Chinese Tech in US Cars May Cut Sales by Almost 26,000, Agency Says
Sep 28, 2024
02:13 PM EDT, 09/27/2024 (MT Newswires) -- New US rules proposed to ban Chinese connected vehicles and Chinese software and hardware in cars may reduce auto sales in the US by up to 25,841 vehicles a year and raise prices, Reuters reported Friday, citing the US Commerce Department. (Market Chatter news is derived from conversations with market professionals globally. This...
Johnson & Johnson Says Darzalex Faspro Showed Increased MRD-Negative Rates in Multiple Myeloma Study
Johnson & Johnson Says Darzalex Faspro Showed Increased MRD-Negative Rates in Multiple Myeloma Study
Sep 28, 2024
02:12 PM EDT, 09/27/2024 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Friday that its phase 3 Auriga study showed Darzalex Faspro plus lenalidomide significantly improved MRD-negative conversion rates at 12 months compared to lenalidomide alone in patients with newly-diagnosed multiple myeloma. The combination also indicated a potential benefit in progression-free survival with no new safety concerns, Johnson...
T-Mobile US Unusual Options Activity For September 27
T-Mobile US Unusual Options Activity For September 27
Sep 28, 2024
Investors with a lot of money to spend have taken a bearish stance on T-Mobile US ( TMUS ) . And retail traders should know. We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know. But when something this...
Copyright 2023-2026 - www.financetom.com All Rights Reserved